文献速递膀胱癌与上尿路尿路上皮癌

人工智能预测性生物标志物阳性与高危非肌层浸润性膀胱癌卡介苗治疗反应差相关,但与序贯吉西他滨/多西他赛无关

Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2025-04-25

本研究在未接受过治疗的高级别非肌层浸润性膀胱癌患者中评估CHAI生物标志物对膀胱内BCG或序贯吉西他滨/多西他赛(Gem/Doce)疗效的预测作用。CHAI阳性患者中,BCG组24个月高级别无复发生存率为56%,Gem/Doce组为90%(HR 5.4,p=0.007);CHAI阴性患者中两组无显著差异(HR 1.3,p=0.5),交互项显著(p=0.029)。提示CHAI生物标志物可识别BCG获益可能较低、或可从Gem/Doce等替代治疗中获益的患者。

要点

  • CHAI阳性患者BCG组24个月HG-RFS为56%,Gem/Doce组为90%(HR 5.4,p=0.007)。
  • CHAI阴性患者中BCG与Gem/Doce的HG-RFS无显著差异(HR 1.3,p=0.5)。
  • CHAI生物标志物与治疗类型的交互项显著(p=0.029),提示疗效关联取决于治疗方式。

核心结论

  • CHAI生物标志物阳性与高级别NMIBC患者BCG治疗后较差的HG-RFS相关,但与Gem/Doce治疗后的HG-RFS无关。
  • CHAI生物标志物可能有助于识别BCG获益较低、或可从Gem/Doce等替代治疗中获益的患者。

研究设计与样本

  • 研究纳入未接受过治疗的高级别NMIBC患者,评估CHAI生物标志物在接受膀胱内BCG或序贯Gem/Doce治疗患者中的预测作用。

主要发现

  • CHAI阳性患者中,BCG组24个月HG-RFS为56%(95%CI 43-73%),Gem/Doce组为90%(95%CI 79-100%),HR 5.4(95%CI 1.6-18.3),p=0.007。
  • CHAI阴性患者中,BCG与Gem/Doce组HG-RFS无显著差异(HR 1.3,95%CI 0.6-2.6,p=0.5)。
  • CHAI生物标志物与治疗类型的交互项显著(p=0.029),提示生物标志物与临床结局的关联取决于所接受的治疗。

关键数值与推荐

  • CHAI阳性且接受BCG治疗者24个月HG-RFS为56%(95%CI 43-73%)。
  • CHAI阳性且接受Gem/Doce治疗者24个月HG-RFS为90%(95%CI 79-100%)。
  • CHAI阳性患者BCG对比Gem/Doce的HR为5.4(95%CI 1.6-18.3),p=0.007。
  • CHAI阴性患者BCG对比Gem/Doce的HR为1.3(95%CI 0.6-2.6),p=0.5。
  • CHAI生物标志物与治疗类型交互项p=0.029。

临床怎么用

  • 对于高级别NMIBC患者,可考虑检测CHAI生物标志物以辅助选择膀胱内BCG或序贯Gem/Doce治疗方案。
  • CHAI阳性患者可能从序贯Gem/Doce治疗中获益更多,而CHAI阴性患者两种治疗的HG-RFS无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intravesical bacillus Calmette-Guerin (BCG) is considered first-line adjuvant therapy for high-risk or high-grade non-muscle-invasive bladder cancer (NMIBC). Recently, sequential intravesical gemcitabine and docetaxel (Gem/Doce) has emerged as a promising alternative to intravesical BCG. Biomarkers to select the optimal treatment regimen could facilitate clinical decision-making. The Computational Histologic Artificial Intelligence (CHAI) platform was previously used to develop an artificial intelligence-augmented histologic assay (CHAI biomarker) that identified patients with NMIBC at an increased risk of recurrence and progression events following BCG treatment. In this study, we assessed use of the CHAI biomarker among patients with treatment-naive high-grade NMIBC who received intravesical BCG or Gem/Doce. Among patients with the presence of the CHAI biomarker, those treated with BCG had a 24-mo high-grade recurrence-free survival (HG-RFS) rate of 56% (95% confidence interval [CI] 43-73%) and those treated with Gem/Doce had an HG-RFS rate of 90% (95% CI 79-100%; hazard ratio [HR] 5.4, 95% CI 1.6-18.3, p = 0.007). Among patients with an absence of the CHAI biomarker, those treated with BCG or Gem/Doce had no significant difference in HG-RFS (HR 1.3, 95% CI 0.6-2.6, p = 0.5). The interaction term between the CHAI biomarker and the treatment type was significant (p = 0.029), indicating an association between the biomarker and the clinical outcome that is dependent on the treatment received. This study suggests that the CHAI biomarker predicts which specific high-grade NMIBC patients are less likely to benefit from BCG and may benefit from alternative treatments including, potentially, Gem/Doce.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Packiam VT, McElree IM, Ghodoussipour S, et al. Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025. PMID: 40287344. doi:10.1016/j.euo.2025.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。